ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone

For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral GLP-1 for obesity—marked an opportunity to recapture some of the ch | For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral GLP-1 for obesity—marked an opportunity to recapture some of the chronic weight management market it had ceded to rival Eli Lilly in the U.S.